Investing.com - Intellia Therapeutics Inc (NASDAQ: NTLA) reported second quarter EPS of $-1.52, $0.30 worse than the analyst estimate of $-1.22. Revenue for the quarter came in at $6.96M versus the consensus estimate of $19.68M.
Intellia Therapeutics Inc's stock price closed at $21.31. It is down -12.88% in the last 3 months and down -47.50% in the last 12 months.
Intellia Therapeutics Inc saw 15 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Intellia Therapeutics Inc's stock price’s past reactions to earnings here.
According to InvestingPro, Intellia Therapeutics Inc's Financial Health score is "fair performance".
Check out Intellia Therapeutics Inc's recent earnings performance, and Intellia Therapeutics Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar